Indian pharma stocks, Feb. 20 -- Macquarie Equity Research has initiated outperform ratings for Divi's Labs, Suven Pharma, Bluejet Healthcare, and Syngene. Among the 11 companies covered in the brokerage's regional Contract Development and Manufacturing Organisation (CDMO) analysis, Macquarie favours Indian and Korean CDMOs, highlighting Divi's Labs and Samsung Bio as their preferred choices.

According to Macquarie Equity Research, the contract research, development, and manufacturing (CRDMO) sector in India is experiencing growth driven by long-term trends and supportive regulatory changes.

According to the brokerage analysis, Indian CDMOs are establishing themselves as frontrunners in the development of small molecules, providing comp...